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Abstract. 
 
Parathyroid hormone–related peptide 
(PTHrP) appears to play a major role in skeletal devel-
opment. Targeted disruption of the PTHrP gene in 
mice causes skeletal dysplasia with accelerated chon-
drocyte maturation (Amizuka, N., H. Warshawsky, J.E. 
Henderson, D. Goltzman, and A.C. Karaplis. 1994. 
 
J. 
Cell Biol.
 
 126:1611–1623; Karaplis, A.C., A. Luz, J. 
Glowacki, R.T. Bronson, V.L.J. Tybulewicz, H.M. 
Kronenberg, and R.C. Mulligan. 1994. 
 
Genes Dev.
 
 8:
277–289). A constitutively active mutant PTH/PTHrP 
receptor has been found in Jansen-type human meta-
physeal chondrodysplasia, a disease characterized by 
delayed skeletal maturation (Schipani, E., K. Kruse, 
and H. Jüppner. 1995. 
 
Science (Wash. DC).
 
 268:98–
100). The molecular mechanisms by which PTHrP af-
fects this developmental program remain, however, 
poorly understood. We report here that PTHrP in-
creases the expression of Bcl-2, a protein that controls 
programmed cell death in several cell types, in growth 
plate chondrocytes both in vitro and in vivo, leading to 
delays in their maturation towards hypertrophy and 
apoptotic cell death. Consequently, overexpression of 
PTHrP under the control of the collagen II promoter in 
transgenic mice resulted in marked delays in skeletal 
development. As anticipated from these results, dele-
tion of the gene encoding Bcl-2 leads to accelerated 
maturation of chondrocytes and shortening of long 
bones. Thus, Bcl-2 lies downstream of PTHrP in a path-
way that controls chondrocyte maturation and skeletal 
development.
 
P
 
arathyroid
 
 hormone–related peptide (PTHrP)
 
1
 
was initially isolated from human carcinomas
(Strewler et al., 1987; Suva et al., 1987; Mangin et
al., 1988) and is responsible for the humoral hypercalce-
mia associated with various malignancies. PTHrP is struc-
turally related to parathyroid hormone (PTH), a hormone
of major importance in calcium metabolism. Both peptides
share 8 of 13 NH
 
2
 
-terminal residues and bind to and acti-
vate the same G-protein–coupled PTH/PTHrP receptor
(Jüppner et al., 1991). Unlike PTH, however, PTHrP does
not circulate in appreciable amounts in normal subjects
but is instead, widely expressed in fetal and adult tissues,
where it is thought to regulate cell differentiation, cell pro-
liferation, and organogenesis as a paracrine or autocrine-
soluble factor (Goltzman et al., 1989; Broadus and Stew-
art, 1994; Wysolmerski et al., 1994). In this context, PTHrP
is a mediator of cellular growth and differentiation (Ami-
zuka et al., 1994; Karaplis et al., 1994) and is involved in
mesenchymal–epithelial interactions in several tissues
(Hardy, 1992; Van de Stolpe et al., 1993; Wysolmerski et
al., 1994).
The critical role played by PTHrP and its receptor in
skeletal development has recently been emphasized by
gene deletion experiments in mice and by a natural muta-
tion in humans. Mice homozygous for PTHrP gene abla-
tion exhibit skeletal deformities that are due to a decrease
in proliferation and the accelerated differentiation of
chondrocytes in the developing skeleton (Amizuka et al.,
1994; Karaplis et al., 1994). At the other end of the spec-
trum, striking skeletal deformities are observed in Jansen’s
metaphyseal chondrodysplasia, a human form of short-
limbed dwarfism with delayed endochondral maturation
(Jansen, 1934). This has been recently attributed to a sin-
gle heterozygous nucleotide exchange in exon M2 of the
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gene encoding for the PTH/PTHrP receptor, resulting in a
constitutively active mutant PTH/PTHrP receptor (Schi-
pani et al., 1995). Although these findings clearly establish
that PTHrP plays a regulatory role in the process of endo-
chondral ossification, the precise mechanism by which
PTHrP affects skeletal development is not known.
During endochondral ossification, the chondrocytes present
in the early cartilaginous model, and later in the growth
plate, first proliferate and then progressively differentiate
into mature hypertrophic chondrocytes. Once fully differ-
entiated, these hypertrophic cells participate in the miner-
alization of the cartilaginous matrix and undergo cell
death. In normal bone development, this is followed by, and
may be the necessary signal for, the local recruitment of
blood vessels and osteoclasts into the zone of provisional
mineralization. This leads to the progressive replacement
of cartilage by bone, the homing of the hematopoietic
bone marrow, and ultimately, longitudinal bone growth. In
bone, osteoblasts and growth plate chondrocytes express
PTH/PTHrP receptors and secrete PTHrP, suggesting the
existence of autocrine/paracrine regulatory loops (Jüpp-
ner et al., 1988; Amizuka et al., 1994). The latter appear to
be essential for normal chondrocyte maturation and/or en-
dochondral bone formation, as shown by the various trans-
genic models and natural mutation discussed above (Ami-
zuka et al., 1994; Karaplis et al., 1994; Schipani et al.,
1995).
Apoptosis has been proposed as the mechanism respon-
sible for the death of chondrocytes during endochondral
bone formation (Farnum and Wilsman, 1989; Lewinson
and Silbermann, 1992). In several cell types, apoptosis is
regulated by the ratio of expression of the cell death inhib-
itor, Bcl-2, and the cell death inducer, Bax. Bcl-2 is the
founding member of an emerging family of proteins whose
function involves the regulation of programmed cell death
(Vaux et al., 1988; Korsmeyer, 1992). Bax is another Bcl-2
family member which forms heterodimers with Bcl-2 and,
when overexpressed, counters the anti-apoptotic effect of
Bcl-2, causing accelerated cell death. Within a cell, it is the
ratio of Bcl-2 to Bax that determines whether a cell dies or
not. It has been shown that apoptosis is repressed when
half or more of the endogenous Bax is heterodimerized
with Bcl-2 (Oltvai et al., 1993; Miyashita et al., 1994; Yin et
al., 1994; Sedlak et al., 1995).
The temporal–spatial distribution of Bcl-2 suggests that
it serves to regulate apoptotic cell death during embryonic
development and in adulthood. Bcl-2 is widely expressed
among fetal tissues, with substantial levels present in the
developing limb bud (Veis Novack and Korsmeyer, 1994),
and apoptosis is now recognized as an important process
in organogenesis and development. In the adult, Bcl-2 ex-
pression is limited to renewing stem cell populations, such
as those found in hematopoietic lineages, complex differ-
entiating epithelia, and glandular epithelia, and to long-
lived postmitotic cell populations (Hockenbery et al.,
1991). Several observations led us to hypothesize that
PTHrP and Bcl-2 might participate in the same regulatory
pathways during skeletal development: (
 
a
 
) the temporal–
spatial similarities of the expression patterns of PTHrP
(Lee et al., 1995) and Bcl-2 (Veis Novack and Korsmeyer,
1994);  and the characteristic changes in endochondral
bone formation due to either the absence of PTHrP (Ami-
zuka et al., 1994) or the constitutive activation of its recep-
tor (Schipani et al., 1995).
We report here that Bcl-2 and Bax are expressed in
chondrocytes in vivo and show a characteristic distribution
within the developing growth plate, which is consistent
with their role in regulating chondrocyte programmed cell
death. Furthermore, we provide evidence that Bcl-2 is a
direct player and not just a bystander in skeletal develop-
ment, since accelerated endochondral bone maturation oc-
curs in 
 
bcl-2
 
 knockout mice, leading to a phenotype paral-
leling that of the PTHrP knockout mice (Amizuka et al.,
1994). Finally, we present in vitro and in vivo evidence, us-
ing transgenic mice with overexpression of PTHrP tar-
geted to chondrocytes, that Bcl-2 is downstream of PTHrP
in a signaling pathway that is required for normal skeletal
development.
 
Materials and Methods
 
Confocal Immunofluorescence Analysis
 
The antibodies used in these experiments include a rabbit anti-mouse col-
lagen type X antibody (dilution 1:100) generously provided by Dr. B. Olsen
(Harvard University, Cambridge, MA), polyclonal antibodies against
mouse Bcl-2 (dilution 1:200) obtained from PharMingen (San Diego,
CA), and Bax (dilution 1:200) obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). The fluorescein-conjugated secondary antibodies (dilu-
tion 1:100) and the normal goat serum were purchased from Boehringer
Mannheim Biochemicals (Indianapolis, IN). For immunofluorescence
analysis, cultured cells plated on glass coverslips, 6 
 
m
 
m frozen sections, and
6 
 
m
 
m paraffin embedded sections of 6-d-old mice [(Procollagen Ia type II)
col II-PTHrP transgenic mice and control littermates] were used. Mice
were perfused via the heart with paraformaldehyde (2%), lysine (0.75 M),
and sodium periodate (0.01 M) (PLP), for 5 min. The long bones were dis-
sected out and fixed in PLP for an additional 4 h at 4
 
8
 
C, washed in PBS for
1 h, and infiltrated overnight with 40% sucrose in PBS. The tissue was
subsequently quick-frozen or embedded in paraffin. The cultured cells
were fixed in 3.7% formaldehyde in PBS for 10 min at room temperature
and washed in PBS. Further processing of tissue sections and isolated cells
was identical. For collagen X staining, the samples were preincubated with
bovine hyaluronidase in PBS (1 mg/ml) for 45 min at 37
 
8
 
C. All subsequent
incubations were performed at room temperature with PBS containing
0.05% saponin, 0.1% BSA, and 5% normal goat serum (NGS). The sam-
ples were incubated in PBS–saponin–BSA–NGS for 30 min to block non-
specific binding, and then for 2 h with the primary antibody. The samples
were washed in PBS–saponin–BSA and incubated with secondary anti-
body for 1 h in the dark. After washing in PBS, the samples were mounted
in FluorSave fluorescent mounting media (Calbiochem-Novabiochem
Corp., La Jolla, CA). Samples were examined with a scanning laser confo-
cal microscope (Axiovert 10, Zeiss, Inc., Thornwood, NY and MRC 600
confocal imaging system; Bio-Rad Laboratories, Richmond, CA) with a
krypton/argon laser using an optical slice thickness of 1–2 
 
m
 
m. Computer
images were collected on optical memory discs and were computer en-
hanced with the Adobe Photoshop program.
 
In situ Analysis of Apoptotic Cells
 
Terminal deoxynucleotidyl transferase (TdT)–mediated dUTP nick end-
labeling (TUNEL) was performed using a molecular biological–his-
tochemical system, ApopTag kit (Oncor, Gaithersburg, MD) for specific
staining of DNA fragmentation and apoptotic bodies (Gavrieli et al., 1992).
Cells exhibiting DNA fragmentation and containing apoptotic bodies,
thereby morphologically consistent with apoptosis, are referred to as apop-
totic cells. TdT, which catalyzes a template-independent addition of deoxy-
ribonucleotide to 3
 
9
 
-OH ends of DNA, was used to incorporate digoxige-
nin-conjugated dUTP to the ends of DNA fragments. Briefly, after
digesting protein in quick-frozen bone sections (control mice and col II-
PTHrP transgenic mice) with 10 
 
m
 
g/ml proteinase K at room temperature
and then quenching endogenous peroxidase activity with 1% H
 
2
 
O
 
2
 
 in
PBS, slides were placed in equilibration buffer, and then in terminal deoxy-
nucleotidyl transferase solution, followed by stop/wash buffer. The signal 
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of TUNEL was then detected by an anti-digoxigenin antibody conjugated
with peroxidase, a reporter enzyme that catalytically generates a brown-
colored product from the chromogenic substrate diaminobenzidine. Be-
cause processing in paraffin may increase the number of apparent apop-
toses, we used cryosections. Controls for specificity of labeling included
positive control slides prepared by nicking DNA with DNAse I (Boeh-
ringer Mannheim Biochemicals) (Arends et al., 1990), and negative con-
trol sections were prepared by substituting distilled water for TdT en-
zyme. The slides were washed, dried, and mounted in Permount media.
 
Cell Cultures
 
Chondrocytes were isolated from the resting zone of the proximal tibia
and distal femur of 10-d–old mice. Growth plates were cleaned of peri-
chondrium; the reserve zone was dissected by a transverse cut through the
calcification zone and separated from the epiphysis under a dissecting mi-
croscope. Pooled growth plates from 10 to 12 animals were predigested
for 30 min in a 0.1% solution of clostridial collagenase Ia (Sigma Chemical
Co., St. Louis, MO) in culture media (Ham F-12/DME 1:1, 10% FBS, 1%
penicillin/streptomycin [PS], 50 
 
m
 
g/ml L-ascorbic acid, 100 
 
m
 
g/ml sodium
pyruvate) in a shaker at room temperature. Cartilage fragments were then
washed twice in culture media and subsequently digested for 3 h, in a
0.2% solution of collagenase in culture media, in an incubator shaker at
37
 
8
 
C. The solution containing the isolated cells was filtered (through 50 
 
m
 
m
mesh), and cells were recovered by centrifugation (1,500 rpm, 4
 
8
 
C, 5 min).
Cells were resuspended in culture medium at a final concentration of
300,000 cells/ml. Cells were cultured as high-density monolayers in 24-well
dishes (150,000 cells/well) (Falcon Labware, Oxnar, CA) and in 60-mm
dishes (10
 
6
 
 cells/dish) for protein extraction. Medium was changed every
other day after the third day. PTH 1-34 and PTHrP 1-37 (both at a final
concentration of 10
 
2
 
7
 
 M) or forskolin (final concentration 50 
 
m
 
M) were
added with fresh media every other day. Mouse primary osteoblastic cells
were obtained from 3-d–old mouse calvaria and cultured in 
 
a
 
MEM con-
taining 10% FBS and 1% PS. The human renal carcinoma cell line
(CAKI) was cultured in RPMI containing 10% FBS and 1% PS. All cul-
tures were maintained at 37
 
8
 
C, gassed with 95% air/5% CO
 
2
 
.
 
Western Blot Analysis
 
All extraction procedures were performed at 4
 
8
 
C. Cells were washed once
with ice-cold PBS, and cell lysates were generated with ice-cold RIPA
buffer (10% mM Tris-HCl, pH 7.2, 158 mM NaCl, 5 mM EDTA, 1% Tri-
ton X-100, 1% sodium deoxycholate, and 0.1% SDS) containing protease
inhibitors (0.1 mM PMSF, 1 
 
m
 
M pepstatin, and 1 
 
m
 
M leupeptin) which dis-
rupt Bcl-2/Bax interactions. RIPA extracts were prepared by sonication
and subsequent centrifugation at 12,000 
 
g
 
 for 10 min. The protein was
eluted by boiling in sample buffer (62.5 mM Tris–HCl, pH 6.9, 2 mM
EDTA, 3% SDS, 3.75% glycerol, and 180 mM 
 
b
 
-mercaptoethanol) for 2
min. Western blotting was performed using the enhanced chemilumines-
cence Western blotting detection reagents (Amersham Corp., Arlington
Heights, IL) according to the conditions recommended by the supplier.
Briefly, samples (chondrocytes and osteoblasts, 200 
 
m
 
g/lane, kidney cells,
100 
 
m
 
g/lane) were analyzed by 12.5% SDS-PAGE followed by electropho-
retic transfer of the proteins to nitrocellulose filters. Filters were first
blocked in TBST (20 mM Tris, pH 7.6, 134 mM NaCl, 0.1% Tween-20)
containing 5% Carnation nonfat dry milk for 2 h and then incubated
with the rabbit anti–Bcl-2 N-19 (Santa Cruz Biotech.) polyclonal anti-
body (1:200 in TBST) for 6 h at 4
 
8
 
C. After three sequential 15 min washes
in TBST, the filters were incubated with anti–rabbit peroxidase-conju-
gated secondary antibody (1:20,000 in TBST) for 1 h at room temperature
and then again washed as described above. For human kidney cells, filters
were first incubated with 5% BSA in TBST, to block nonspecific binding,
and then with monoclonal mouse anti–human Bcl-2 124 (dilution 1:200 in
TBST) (DAKO Corp., Carpinteria, CA); anti–mouse peroxidase-conju-
gated secondary antibody was used as described above. Bound protein
was detected by enhanced chemiluminescence reaction. The blots were
then stripped of antibody and reprobed with anti-actin monoclonal anti-
body (Boehringer Mannheim Biochemicals, 1 
 
m
 
g/ml) to confirm that
equal amounts of protein were loaded in each corresponding treated and
untreated lane.
 
Generation and Analysis of col II-PTHrP
Transgenic Mice
 
Transgenic mice were generated as previously described (Weir et al., 1996).
Briefly, a 568-bp human PTHrP cDNA fragment encoding the 1-141 iso-
form was inserted into a 6.5-kb segment of the mouse procollagen a1 type
II (col II) promoter region (obtained from S. Garofolo, Shriners Hospital,
Portland, OR and B. de Crombrugghe, M.D. Anderson Cancer Center,
Houston, TX) at a site within the first intron. A consensus splice acceptor
(courtesy of P. Soriano, Fred Hutchinson Cancer Research Center, Seat-
tle, WA) was included in the col II construct at the 5' end of the insertion
point to create an artificial exon and thus circumvent alternative splicing.
The initiation codon in exon 1 of the procollagen gene was inactivated to
allow translation to start within the cDNA sequences. Also, a 2.2-kb seg-
ment of the human growth hormone gene was added downstream of the
cDNA to provide termination/polyadenylation signals and to increase ex-
pression efficiency. The growth hormone coding sequences are not trans-
lated.
For histology, col II-PTHrP transgenic mice and control littermates (6 d
of age) were perfused via the heart with PLP for 5 min. Metatarsals were
dissected out and fixed by 3.7% paraformaldehyde for 12 h at 4
 
8
 
C, embed-
Figure 1. Expression of Bcl-2 and Bax in endochondral bone formation. (A) The normal growth plate shows a typical zonal structure of
differentiating chondrocytes. Proliferating chondrocytes (P) progressively enlarge to prehypertrophic chondrocytes (PH), and further dif-
ferentiate into hypertrophic chondrocytes (H). (B) Age-matched growthplates were labeled by immunofluorescence for collagen type X,
which serves as a specific marker in the chondrocyte differentiation process. Intracellular expression of collagen X is characteristic of pre-
hypertrophic chondrocytes, whereas the dense, pericellular matrix labeling shown in red is found solely in the hypertrophic zone. (C)
Highest levels of Bcl-2 protein are detected in late proliferative and prehypertrophic chondrocytes, whereas, (D), hypertrophic chondro-
cytes exhibit an increased Bax protein expression. Age-matched frozen sections were labeled for DNA fragmentation by TUNEL. (E)
Nick end labeling of DNA fragments was observed only in fully differentiated hypertrophic chondrocytes, at the level where resorption
of cartilage and replacement by bone is taking place. 
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ded in epon, and 2 
 
m
 
m sections were prepared on a ultramicrotome (Rei-
chert Scientific Instruments, Buffalo, NY). Sections were stained with
toluidine blue and evaluated on a Reichert microscope (UnivaR, C. Rei-
chert, Austria). Immunohistochemical analysis and TUNEL analysis were
done as stated above for confocal immunfluorescence analysis and in situ
analysis of apoptotic cells, respectively.
 
Generation and Histology of bcl-2 Knockout Mice
 
Generation of germ line mutant mice carrying ablated 
 
bcl-2
 
 coding re-
gions was previously described (Nakayama et al., 1993; 1994). Offspring
from heterozygote intercrosses were genotyped by PCR and by Southern
blot analysis, as previously reported (Nakayama et al., 1993; 1994). After
radiological analysis of the skeleton, histomorphometric analysis was per-
formed on undecalcified, processed bones of neonate, 6-d, and 60-d–old
knockout mice and control littermates (Hahn et al., 1991). Three samples
each were analyzed, and statistical analysis was performed using Student’s
 
t
 
 test.
 
Results
 
Localization of Bcl-2 and Bax in Normal Growth Plates
 
Bcl-2 protein is expressed in chondrocytes throughout the
growth plate, with highest levels in late proliferative and
prehypertrophic chondrocytes (characterized by their in-
tracellular expression of collagen type X), and markedly
decreased levels in late hypertrophic chondrocytes (char-
acterized by their morphology and pathognomonic, peri-
cellular, ring-like secretion of collagen type X) (Fig. 1, 
 
A–C
 
).
The opposite pattern was observed for Bax protein ex-
pression, with undetectable levels in proliferative cells and
a progressive increase towards hypertrophic chondrocytes
(Fig. 1 
 
D
 
). Thus, within the growth plate, the ratio of Bcl-2
to Bax progressively decreases in favor of Bax, and fully
differentiated (hypertrophic) chondrocytes die in an apop-
totic manner, as confirmed by nick end-labeling of DNA
fragments by TUNEL (Gavrieli et al., 1992) (Fig. 1 
 
E
 
).
 
PTHrP Increases Bcl-2 Expression in Chondrocytes
In Vitro
 
Treatment of cultured murine growth plate chondrocytes
with the NH
 
2
 
-terminal fragments PTHrP 1-37 (Figs. 2 and 3)
or PTH 1-34 (data not shown) resulted in an increase in
cAMP production and a marked increase in Bcl-2 expres-
sion. By comparing pixel intensity of Bcl-2 immunolabel-
ing, differences in Bcl-2 levels in treated and untreated
chondrocyte cultures were clearly detectable, with a two-
fold increase in treated culture, as early as 3 d after start-
ing PTHrP treatment, i.e., before the appearance of hyper-
trophic cells (data not shown). In parallel, in longer cultures
(12 or 24 d), we observed an inhibition of chondrocyte dif-
ferentiation, as determined by reduced expression of alka-
line phosphatase and matrix calcification (data not shown);
a marked decrease in the number of hypertrophic cells;
and an accumulation of prehypertrophic chondrocytes
Figure 2. PTHrP increases Bcl-2
expression in chondrocytes in
vitro. (A) Murine chondrocytes,
cultured for 24 d as high-density
monolayers, differentiated in
vitro into hypertrophic chondro-
cytes with the typical extracellu-
lar matrix pattern of collagen X
(compare to Fig. 1 B). (B) In
contrast, treatment of these cul-
tures with PTHrP 1-37 resulted
in an inhibition of terminal dif-
ferentiation and an accumula-
tion of prehypertrophic chondro-
cytes, as confirmed by the
pathognomonic intracellular col-
lagen X expression. After 12 d in
culture, a time at which treated
and untreated cultures show no
apparent morphological differ-
ences, (C) the untreated chon-
drocytes show only low cytoplas-
mic Bcl-2 protein expression,
whereas, (D), a marked increase
in Bcl-2 expression is visible af-
ter PTHrP treatment. In con-
trast, the same treatment had no
detectable effect on the level of
Bax protein expression (E, con-
trol; F, treated). Bars, 10 mm. 
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(Fig. 2, 
 
A
 
 and 
 
B
 
). This increase in Bcl-2 expression was
found to be cAMP dependent and was mimicked in these
cultures by the addition of Forskolin (data not shown).
Bax expression was lower and was not affected by PTH or
PTHrP treatment (Fig. 2 
 
E
 
). Thus, in vitro treatment of
chondrocytes with PTH or PTHrP results in a shift of the
Bcl-2/Bax ratio in favor of Bcl-2, a change that delays termi-
nal differentiation, prolongs chondrocyte survival, and leads
to the accumulation of cells in their prehypertrophic stage.
As shown in Fig. 3, the effects of PTHrP on Bcl-2 ex-
pression were found to be restricted to chondrocytes, since
treating both primary osteoblasts and a kidney cell line,
that expresses the PTH/PTHrP receptor, with PTH or
PTHrP failed to alter Bcl-2 levels in these other cell types,
despite the fact that they responded to PTH/PTHrP with
the expected increase in cAMP.
 
Targeted Overexpression of PTHrP to Chondrocytes In 
Vivo Leads to Increased Bcl-2 Expression and Delayed 
Skeletal Development
 
Targeted overexpression of PTHrP to chondrocytes, using
the collagen type II promoter in transgenic mice, leads to a
profound delay in endochondral bone formation with Jan-
sen’s metaphyseal dysplasia–like skeletal abnormalities
(Weir et al., 1996). As shown on Fig. 4, this also leads to a
marked increase in Bcl-2 expression in prehypertrophic
chondrocytes, with no detectable change in Bax levels. At
6 d of age, the metatarsals of col II–PTHrP transgenic ani-
mals were still at the cartilaginous model stage with an
accumulation of prehypertrophic chondrocytes, thereby mim-
icking the effects of PTHrP on chondrocytes in culture.
These cells contained intracellular collagen type X (data
not shown). Hypertrophic or apoptotic chondrocytes were
not detectable, as further confirmed by the absence of ex-
tracellular collagen type X rings and signal from TUNEL
analysis (data not shown). In contrast with control litter-
mates, the formation of bone or bone marrow was not yet
apparent in the transgenic animals (Fig. 4).
 
Accelerated Endochondral Bone Formation in bcl-2 
Knockout Mice
 
To determine whether Bcl-2 is directly involved in endo-
chondral bone formation and whether its characteristic ex-
pression pattern within the growth plate is related to a
functional role in regulating chondrocyte terminal differ-
entiation, we analyzed the skeleton in 
 
bcl-2
 
 knockout
mice. We found that 
 
bcl-2
 
 knockout mice exhibit prema-
ture chondrocyte maturation and terminal differentiation.
Consequently, the program of endochondral bone forma-
tion is significantly accelerated, leading to earlier vascular
invasion, replacement of cartilage by bone, and homing of
bone marrow cells, as compared to control littermates
(Fig. 5). Furthermore, 
 
bcl-2
 
 knockout mice exhibit a re-
duction in the growth plate thickness, mostly due to a de-
crease in the height of proliferative zone, and ultimately a
significant decrease (15%–20%) in overall bone length.
These data demonstrate that Bcl-2 is a direct player in the
regulation of the endochondral bone formation and that
 
bcl-2
 
 knockout mice display a skeletal phenotype parallel-
ing that of PTHrP knockout mice, though far less pro-
nounced (Fig. 5).
 
Discussion
 
The present study suggests that PTHrP, a major player in
chondrocyte maturation and endochondral bone forma-
tion, exerts its effect on skeletal development via a path-
way involving Bcl-2 expression and alterations in chondro-
cyte maturation and apoptotic cell death.
Bcl-2 is expressed in chondrocytes throughout the growth
plate, with highest levels in late proliferative and prehy-
pertrophic chondrocytes, and markedly decreased levels in
late hypertrophic chondrocytes, a pattern of expression
similar to that of PTHrP (Amizuka et al., 1994). The oppo-
site pattern was observed for Bax expression, with unde-
tectable levels in proliferative cells and a progressive in-
crease towards hypertrophic chondrocytes. Thus, within
the growth plate, the ratio of Bcl-2 to Bax progressively
decreases in chondrocytes in favor of Bax. This should re-
sult in the apoptotic death (Oltvai et al., 1993) of fully dif-
ferentiated (hypertrophic) chondrocytes, as confirmed by
morphology and nick end-labeling of DNA fragments by
TUNEL and previously suggested by others (Farnum and
Wilsman, 1989; Lewinson and Silbermann, 1992; Hender-
son et al., 1995).
The presence of short ears and short and deformed
limbs in the 
 
bcl-2
 
 knockout mice (Nakayama et al., 1993;
Nakayama et al., 1994; Veis et al., 1993) also suggests a
functional role for Bcl-2 in chondrocyte maturation. To di-
rectly study the role of Bcl-2 in chondrocyte differentia-
tion, we analyzed the skeletal phenotype in 
 
bcl-2
 
 knock-
out. We found that despite the existence of nine family
members and efficient redundancies, the pathway of endo-
chondral bone formation is significantly altered in 
 
bcl-2
 
knockout mice. A marked reduction in growth plate thick-
Figure 3. PTHrP effect on Bcl-2 is restricted to chondrocytes.
Western blotting analysis revealed that treatment of murine
chondrocytes in vitro (cultured for 12 d) with PTHrP 1-37 re-
sulted in a marked increase in Bcl-2 expression. In contrast, the
same treatment had no detectable effect on Bcl-2 levels in pri-
mary osteoblasts, obtained from 3-d–old mouse calvaria, and a
kidney cell line (CAKI), both of which express the PTH/PTHrP
receptor. The blots were then stripped of antibody and reprobed
with anti-actin antibody to confirm that equal amounts of protein
were loaded in each corresponding treated and untreated lane. 
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ness, predominantly due to a shortening of the prolifera-
tive zone, and a significant decrease in overall bone length,
provided evidence for accelerated chondrocyte differenti-
ation. This firmly established that Bcl-2 is directly involved
and required for normal skeletal development.
Since absence of PTHrP in the null mutant leads to ac-
celerated chondrocyte differentiation in the growth plate
(Amizuka et al., 1994; Karaplis et al., 1994), we and others
(Amizuka et al., 1994; Henderson et al., 1995) hypothe-
sized that this could be due to an increase in programmed
cell death. To further test this hypothesis and to study the
mechanisms by which PTHrP delays chondrocyte differen-
tiation (Kato et al., 1990; Iwamoto et al., 1994; Klaus et al.,
1994) and apoptotic cell death (Henderson et al., 1995), we
first determined whether PTHrP could alter Bcl-2 expres-
sion in chondrocytes. We found that in vitro treatment of
chondrocytes with PTH or PTHrP results in a shift of the
Bcl-2/Bax ratio in favor of Bcl-2, a change that delays ter-
minal differentiation and apoptosis of hypertrophic chon-
drocytes and leads to the accumulation of cells in their
prehypertrophic stage.
Despite the fact that other cell types are known to ex-
press PTH/PTHrP receptors and to respond to PTHrP
with an increase in cAMP, the only alterations reported in
the PTHrP knockout mice, and in individuals with the re-
ceptor mutation, are chondrodysplasias. We consequently
determined whether the effects of PTHrP on Bcl-2 expres-
sion in chondrocytes were cell-specific, by treating primary
osteoblasts and a kidney cell line that expresses the PTH/
PTHrP receptor with PTH or PTHrP. While responding to
Figure 4. Targeted overexpression of PTHrP to chondrocytes in transgenic animals leads to increased Bcl-2 expression and delayed
chondrocyte maturation. (A) Metatarsals of a normal 6-d–old mouse, showing the zonal structures of a growth plate, trabecular and cor-
tical bone, and the presence of a marrow cavity. In contrast (B), the metatarsal of the col II–PTHrP transgenic littermate demonstrates
a delay in chondrocyte differentiation, an accumulation of prehypertrophic chondrocytes (as confirmed by intracellular collagen X ex-
pression, data not shown), and the complete absence of bone formation. At a higher magnification of the insets in A and B, the progres-
sion of chondrocyte differentiation is visible in the normal growth plate: proliferating cells differentiate first into prehypertrophic cells,
and after further enlargement, they finally die at the border to bone formation (compare to Fig. 1) (C). In contrast, the same region in
the metatarsal of the col II–PTHrP transgenic mouse shows that the cells accumulate at the prehypertrophic stage (D). Frozen sections
of the corresponding growth plate regions labeled for Bcl-2 and Bax by immunofluorescence demonstrate the normal pattern of Bcl-2
expression in the growth plate, with highest levels in the zone of prehypertrophic chondrocytes, (E). In contrast, in the col II–PTHrP
transgenic animals, not only the number of chondrocytes expressing Bcl-2 but also the level of Bcl-2 expression are markedly increased
(F); panels G and H demonstrate that Bax expression is not affected in the col II–transgenic animals (H) and is comparable to normal
levels in prehypertrophic chondrocytes (G). 
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Figure 5. Bcl-2 directly affects skeletal development and endo-
chondral bone formation. bcl-2 knockout mice exhibit acceler-
ated chondrocyte differentiation. (A) While under normal condi-
tions at day 1, the foot middle phalanx is still a cartilaginous
model. (B) In bcl-2 knockout littermates, vascular invasion, pro-
gressive replacement of cartilage by bone, and homing of bone
marrow cells has already taken place. (D) This acceleration of
chondrocyte differentiation leads to a reduction in the growth
plate thickness, mostly in the proliferative zone (P), shown here
for the distal metatarsal bone of a 6-d–old bcl-2 knockout mouse
as compared to a 6-d–old normal control (C). Even more striking
is the almost complete loss of cartilage at the proximal end of the
metatarsal bones (day 6) in the bcl-2 2/2 (F), while in the normal
mice, the present zone of chondrocytes is still a resource of bone
formation (E). Consequently, bcl-2 knockout mice are markedly
smaller than control littermates (G) (contact x-ray of 60-d-old
mice; on the right bcl-2 2/2, on the left normal control litter-
mate), and the absence of Bcl-2 leads to a significant decrease
(15%–20%) in overall bone length (H). Significant levels of P ,
0.05, Student’s t test, are indicated by asterisks.
PTH/PTHrP with the expected increase in cAMP produc-
tion, this treatment had no detectable effect on Bcl-2 or
Bax levels in these two cell types. We therefore concluded
that the downstream effect of PTH/PTHrP on Bcl-2 ex-
pression is, at least among those cells that are known to ex-
press the PTH/PTHrP receptor, specific for chondrocytes.
These findings are entirely consistent with the seemingly
chondrocyte-specific abnormalities in the PTHrP knockoutThe Journal of Cell Biology, Volume 136, 1997 212
mice (Amizuka et al., 1994; Karaplis et al., 1994), as well as
in individuals with Jansen’s-type metaphyseal chondrodys-
plasia (Schipani et al., 1995; Jüppner, 1996). This specific-
ity may be due to the fact that in chondrocytes, Bcl-2 may
alter an antioxidative pathway to repress cell death (All-
sopp et al., 1993; Boise et al., 1993; Hockenbery et al.,
1993; Kane et al., 1993), since chondrocytes have been
shown to be resistant to various stresses, such as the with-
drawal of growth factors or serum starvation, as long as
antioxidants are also present (Tschan et al., 1990; Ishizaki
et al., 1994). These cells literally commit suicide in re-
sponse to nitric oxide (Blanco et al., 1995).
The most compelling evidence that the regulation of
Bcl-2 in chondrocytes is a key mechanism by which PTHrP
exerts its control on endochondral ossification during skel-
etal development, however, comes from our recent ob-
servations in vivo. Targeted overexpression of PTHrP to
chondrocytes using the collagen type II promoter in trans-
genic mice leads to a profound delay in endochondral
bone formation with Jansen’s-like skeletal abnormalities
(Weir et al., 1996). We show here that this targeted over-
expression of PTHrP also induces a marked increase in
Bcl-2 expression (fourfold increase) in prehypertrophic
chondrocytes, with no detectable change in Bax levels.
The observation that levels of Bcl-2 expression in chon-
drocytes of the col II-PTHrP transgenic animals were
markedly higher than that of growth plate chondrocytes in
control animals, further indicates that Bcl-2 lies down-
stream of PTHrP, rather than PTHrP directly inhibiting
differentiation, and thereby keeping the cells at a stage in-
trinsically programmed to produce Bcl-2.
We therefore conclude that the apoptotic inhibitor, Bcl-2,
is involved in the regulation of the programmed cell death
of hypertrophic chondrocytes in the growth plate, an event
that is critical for endochondral ossification and skeletal
development. PTH/PTHrP increases the expression of
Bcl-2 in chondrocytes in a cell-specific manner, thereby
delaying their terminal differentiation and subsequent ap-
optosis, and regulating the maturation of the growth plate.
We propose that this regulation may be the mechanism
underlying the chondrodysplasias observed in the PTHrP
knockout mice, in the mice with targeted overexpression
of PTHrP in cartilage, and in human Jansen-type meta-
physeal chondrodysplasia. These findings are entirely con-
sistent with the alterations in endochondral bone for-
mation reported here after manipulating Bcl-2 levels
independently of PTHrP. Thus, as would be expected if
one was lying downstream of the other, the changes in the
bcl-2 knockout mice are similar, though far less pro-
nounced, to those in the PTHrP knockout mice, i.e., accel-
erated chondrocyte maturation. The fact that the bcl-2
knockout mice show a phenotype which is less severe than
that in the mice lacking PTHrP (Amizuka et al., 1994;
Karaplis et al., 1994) is most likely due to the fact that the
function of Bcl-2 during endochondral bone formation can
be in part compensated for by redundant pathways, possi-
bly involving other Bcl-2 family members. Although we
were not able to detect Bcl-x in the normal growth plate,
redundancy is a very likely explanation, since compensa-
tion of the absence of Bcl-2 expression by the other 9 Bcl-2
family members has been previously described in different
cell systems (Reed, 1995; Han et al., 1996).
These observations directly establish the functional role
of Bcl-2 in endochondral bone formation. However, it still
remains to be determined whether the regulation of Bcl-2
expression by PTHrP is of relevance to tumorigenesis: if
the upregulation of PTHrP, which is known to occur in
several malignancies, affects the level of Bcl-2 expression,
it might thereby increase the malignant potential of a tu-
mor by repressing the death of tumor cells due to this au-
tocrine/paracrine pathway. Preliminary data analyzing the
coexpression of PTHrP and Bcl-2 in human chondrosarco-
mas (Pösl et al., 1996) further confirms the importance of
the PTHrP/Bcl-2 pathway, at least in chondrogenic tu-
mors, where the level of coexpression of PTHrP and Bcl-2
seems to be correlated with the degree of malignancy of
the tumor. Thus, Bcl-2 is the first in a new category of
proto-oncogenes that oppose apoptosis and extend cell
survival rather than promote proliferation (Vaux et al.,
1988; Korsmeyer, 1992). We show here that it may be in-
volved in both physiological development and tumorigen-
esis of the skeleton.
Most recently, Indian hedgehog protein was found to be
upstream of PTHrP in the control of chondrocyte differen-
tiation (Lanske et al., 1996; Vortkamp et al., 1996). Our
observations suggest that Bcl-2 acts downstream of PTHrP
in the same pathway, slowing down chondrocyte matura-
tion during normal skeletal development.
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